AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05357378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.
Description: Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~* Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew Anthology® Total Hip System in combination with R3® Acetabular System.
Study NCT05679362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online brief CBT intervention
Description: Cognitive behavioral therapy
Study NCT05918380 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PAL2
Description: Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education.
Study NCT05918380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CINEMA
Description: High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
Study NCT03927066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
Study NCT05313425 — intervention group
Intervention type: OTHER
Intervention: Ectohylo (R) eye drops
Description: using Ectohylo eye drops post operative after PRK in the right eyes of the patients
Study NCT05567874 — intervention group
Intervention type: OTHER
Intervention: Nosocomial SARS-COV 2 Infection proportion
Description: Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
Study NCT05385679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Extraction of lower third molar
Description: The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
Study NCT06166628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Geniculate artery embolization
Description: Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
Study NCT06166628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve phenol nerve ablation
Description: A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
Study NCT06166628 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Skin infiltration of 2cc of 0.25% bupivacaine at the knee
Description: A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
Study NCT05527457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: 160 μg BAY2586116 nasal spray application
Study NCT05527457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline) nasal spray application
Study NCT06395844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METR-NK cell(Metabolic Remodeling Nature Killer Cells)
Description: The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
Study NCT04977206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutual Goal-Setting Education
Description: Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
Study NCT05286593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Study NCT05286593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
Study NCT05286593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Study NCT04981275 — intervention group
Intervention type: OTHER
Intervention: No intervention study
Description: This observational study will only collect data, not provide any intervention to participants.
Study NCT06202196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk prevention session
Description: The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS).
Study NCT06202196 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Therapeutic Patient Education (TPE) management
Description: The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
Study NCT06364709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Criterion-learning practice
Description: The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
Study NCT05356156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the mesenteric defects
Description: The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
Study NCT05356156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-closure of the mesenteric defects
Description: The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
Study NCT04119271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breathe Easy at Home Kit Products
Description: HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
Study NCT06646484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impedancemetry evaluation
Description: Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
Study NCT06413290 — intervention group
Intervention type: OTHER
Intervention: PIFP block group
Description: Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery
Study NCT06413290 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: No intervention
Study NCT05215548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracic surgery
Description: The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
Study NCT05215548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
Study NCT05215548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Description: The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
Study NCT06533436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corded tube care
Description: The caregiver cut a 6 cm strip of Tensoplast® and wrapped it around the intubation probe at the level of the prescribed fixation mark at the corner of the mouth. The cord strands are placed around the patient's head, tightened, and a double knot is tied at the patient's cheek. Compresses are placed over the ears to protect them from possible lesions caused by the cords.
Study NCT06533436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube care attached by AnchorFast
Description: Shaving is recommended for patients with beards, and prior family consent is required for patients with beards.~AnchorFast is Suitable for intubation probes from 5 to 10 mm in diameter, it adapts to different morphologies thanks to hydrocolloid dressings bonded to the face and an adjustable cord around the neck. Due to its rigidity, this device is not recommended for patients whose condition requires them to be positioned in the ventral decubitus (VD) or lateral decubitus position.
Study NCT06533436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Caregiver's evaluation on each tube fixation
Description: The caregivers who performs the interventions according to the study will fill question form to assess the worload and the confort of the tube care for each intervention type The caregivers are both a research actor and a study population. One of the secondary aims of this study is to evaluate the two types of tube-fixing with regard to caregiver workload and comfort in performing care. Caregivers will complete identical questionnaires assessing their satisfaction with the two types of tube fixation studied in arms 1 and 2.
Study NCT05424640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 1
Description: Description in the arm description
Study NCT05424640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 2
Description: Description in the arm description
Study NCT05424640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 3
Description: Description in the arm description
Study NCT05424640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 4
Description: Description in the arm description
Study NCT04687514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
Study NCT04687514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
Study NCT04696211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-with-movement exercise
Description: A music-with-movement exercise programme to reduce chronic pain in older adults.
Study NCT04525963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative visit of the operating room nurse and patient education
Description: The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
Study NCT05039060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified MAC diet (3-weeks)
Description: * Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis
Study NCT05039060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified MAC diet (3-weeks)
Description: * Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis
Study NCT05628922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months.
Study NCT05628922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent chemoradiation
Description: Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles.
Study NCT04991090 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: escalation dose of LLNs
Description: The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV
Description: Pressure support ventilation applied from the start of subcutaneous suture until extubation.
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Manual Assistance
Description: Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG-Guidance
Description: Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obey Command
Description: Extubation criteria include obeying commands (eye-opening or handgrip).
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Respiration
Description: Extubation criteria include:~Tidal volume > 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min
Study NCT06165562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous Respiration
Description: Extubation criteria include:~Tidal volume > 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min
Study NCT04231084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasodilator testing (Inhaled Nitric Oxide)
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Study NCT04231084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilator testing (Inhaled Epoprostenol)
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Study NCT05161611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: 10 mg of oral zinc sulfate will be given to neonates per day
Study NCT05161611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg of normal saline will be given to neonates per day
Study NCT05161611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: Neonates will be put under phototherapy
Study NCT05161611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Neonates will be put under phototherapy
Study NCT05633485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation-Supported Education
Description: Expert support was received for the design and preparation of animation videos.
Study NCT05070286 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational Study.
Description: Semi-structured interviews.
Study NCT05603429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Description: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
Study NCT06543433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skincubator 2
Description: The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator.
Study NCT05436548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervisor-employee frequent check-ins to identify and address work stressors
Description: Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
Study NCT05436548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual practice waitlist controls
Description: If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
Study NCT05721066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ClotPro assessment
Description: Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)